Skip to content

Ultrasound guided stellate ganglion block in the treatment of acute herpes zoster in head and neck

Ultrasound guided stellate ganglion block in the treatment of acute herpes zoster in head and neck

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018259
Enrollment
Unknown
Registered
2018-09-07
Start date
2018-09-15
Completion date
Unknown
Last updated
2018-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herpes zoster

Interventions

experimental group:medecation+stellate ganglion block

Sponsors

The First Affiliated Hospital of Shihezi University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients aged 50 years or older were diagnosed with head and facial herpes zoster; 2. Patients with rash within 2 weeks and receiving appropriate antiviral treatment.

Exclusion criteria

Exclusion criteria: 1. Patients refused to participate in the study; 2. Those who erupt for more than two weeks; 3. Those who did not receive appropriate antiviral therapy; 4. The head and neck were found to have neurological deficits or SCB infection; 5. Those who have cardiovascular, liver, blood, endocrine or other systemic diseases that make it difficult to complete clinical trials or to analyze the results of research; 6. Patients with diabetic neuralgia have a definite history of diabetes and diabetic peripheral neuropathy (DPN); 7. This study was preceded by SGB or other sympathetic blockades or a history of allergy to research drugs, drug excipients, or chemically similar drugs; 8. Having a history of autoimmune diseases, malignant diseases or known human acquired immunodeficiency syndrome (AIDS); 9. Can not cooperate with SGB or can not tolerate oral medication or have a history of obvious absorption disorders. 10. There was a history of drug abuse or alcohol abuse within 12 months before the start of the study; 11. Other research drugs were taken within 30 days before the start of the study; 12. During the study period, medication or other treatment is not acceptable; 13. Failure to complete the study due to mental illness or any other illness, interference with the clinical course of the study, or significant risk to the patient.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale;

Secondary

MeasureTime frame
PSQI;PCT;CRP;Norepinephrine;

Countries

China

Contacts

Public ContactYang Han

The First Affiliated Hospital of Shihezi University

619807128@qq.com+86 18199664796

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026